• Monica Fung, Charles Y Chiu, Catherine DeVoe, Sarah B Doernberg, Brian S Schwartz, Charles Langelier, Timothy J Henrich, Deborah Yokoe, John Davis, Steven R Hays, Sindhu Chandran, Jasleen Kukreja, Dianna Ng, John Prostko, Russell Taylor, Kevin Reyes, Emma Bainbridge, Allison Bond, Peter Chin-Hong, and Jennifer M Babik.
• Division of Infectious Disease, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
• Am. J. Transplant. 2020 Nov 1; 20 (11): 3225-3233.

AbstractThe coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features, disease course, and serologic response of COVID-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed risk for more severe disease, are not well characterized. We describe our institutional experience with COVID-19 among 10 SOT patients, including the clinical presentation, treatment modalities, and outcomes of 7 renal transplant recipients, 1 liver transplant recipient, 1 heart transplant recipient, and 1 lung transplant recipient. In addition, we report the serologic response in SOT recipients, documenting a positive IgG response in all 7 hospitalized patients. We also review the existing literature on COVID-19 in SOT recipients to consolidate the current knowledge on COVID-19 in the SOT population for the transplant community.© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.

25 keywords...

hide…